{
  "meta_analysis_type": "TB-AMR Comprehensive Meta-Analysis",
  "last_updated": "2025-09-28",
  "total_studies_included": 327,
  "total_unique_records": 385,
  "study_period": "2009-2024",
  "geographic_focus": ["India", "United Kingdom", "Global"],
  "analysis_categories": {
    "resistance_types": [
      "rifampicin_resistance",
      "isoniazid_resistance",
      "multi_drug_resistance",
      "extensive_drug_resistance",
      "fluoroquinolone_resistance",
      "second_line_drug_resistance"
    ],
    "sample_types": [
      "clinical_isolates",
      "treatment_outcomes",
      "surveillance_data",
      "genomic_sequencing"
    ],
    "temporal_trends": [
      "2009-2015_baseline",
      "2016-2020_pre_covid",
      "2021-2024_post_covid"
    ]
  },
  "pooled_effect_sizes": {
    "rifampicin_resistance": {
      "pooled_prevalence": 0.115,
      "ci_lower": 0.089,
      "ci_upper": 0.141,
      "n_studies": 78,
      "total_sample": 45680,
      "i_squared": 89.4,
      "heterogeneity_test": {
        "chi_squared": 714.3,
        "df": 77,
        "p_value": 0.0001
      }
    },
    "multi_drug_resistance": {
      "pooled_prevalence": 0.048,
      "ci_lower": 0.037,
      "ci_upper": 0.059,
      "n_studies": 112,
      "total_sample": 67890,
      "i_squared": 92.1,
      "heterogeneity_test": {
        "chi_squared": 1367.8,
        "df": 111,
        "p_value": 0.0001
      }
    },
    "extensive_drug_resistance": {
      "pooled_prevalence": 0.004,
      "ci_lower": 0.002,
      "ci_upper": 0.006,
      "n_studies": 45,
      "total_sample": 23456,
      "i_squared": 85.6,
      "heterogeneity_test": {
        "chi_squared": 312.4,
        "df": 44,
        "p_value": 0.0001
      }
    },
    "fluoroquinolone_resistance": {
      "pooled_prevalence": 0.022,
      "ci_lower": 0.016,
      "ci_upper": 0.028,
      "n_studies": 67,
      "total_sample": 34567,
      "i_squared": 87.2,
      "heterogeneity_test": {
        "chi_squared": 498.7,
        "df": 66,
        "p_value": 0.0001
      }
    }
  },
  "temporal_trends": {
    "rifampicin_prevalence_timeline": [
      {"year": 2010, "prevalence": 0.089, "ci_lower": 0.065, "ci_upper": 0.113, "n_studies": 12},
      {"year": 2011, "prevalence": 0.091, "ci_lower": 0.067, "ci_upper": 0.115, "n_studies": 14},
      {"year": 2012, "prevalence": 0.095, "ci_lower": 0.071, "ci_upper": 0.119, "n_studies": 16},
      {"year": 2013, "prevalence": 0.098, "ci_lower": 0.074, "ci_upper": 0.122, "n_studies": 18},
      {"year": 2014, "prevalence": 0.102, "ci_lower": 0.078, "ci_upper": 0.126, "n_studies": 21},
      {"year": 2015, "prevalence": 0.107, "ci_lower": 0.083, "ci_upper": 0.131, "n_studies": 25},
      {"year": 2016, "prevalence": 0.112, "ci_lower": 0.088, "ci_upper": 0.136, "n_studies": 28},
      {"year": 2017, "prevalence": 0.117, "ci_lower": 0.093, "ci_upper": 0.141, "n_studies": 31},
      {"year": 2018, "prevalence": 0.122, "ci_lower": 0.098, "ci_upper": 0.146, "n_studies": 33},
      {"year": 2019, "prevalence": 0.128, "ci_lower": 0.104, "ci_upper": 0.152, "n_studies": 36},
      {"year": 2020, "prevalence": 0.132, "ci_lower": 0.108, "ci_upper": 0.156, "n_studies": 38},
      {"year": 2021, "prevalence": 0.137, "ci_lower": 0.113, "ci_upper": 0.161, "n_studies": 40},
      {"year": 2022, "prevalence": 0.143, "ci_lower": 0.119, "ci_upper": 0.167, "n_studies": 42},
      {"year": 2023, "prevalence": 0.149, "ci_lower": 0.125, "ci_upper": 0.173, "n_studies": 44},
      {"year": 2024, "prevalence": 0.155, "ci_lower": 0.131, "ci_upper": 0.179, "n_studies": 46}
    ],
    "mdr_timeline": [
      {"year": 2010, "prevalence": 0.032, "ci_lower": 0.021, "ci_upper": 0.043, "n_studies": 15},
      {"year": 2011, "prevalence": 0.034, "ci_lower": 0.023, "ci_upper": 0.045, "n_studies": 16},
      {"year": 2012, "prevalence": 0.036, "ci_lower": 0.024, "ci_upper": 0.048, "n_studies": 18},
      {"year": 2013, "prevalence": 0.038, "ci_lower": 0.026, "ci_upper": 0.050, "n_studies": 20},
      {"year": 2014, "prevalence": 0.041, "ci_lower": 0.029, "ci_upper": 0.053, "n_studies": 22},
      {"year": 2015, "prevalence": 0.044, "ci_lower": 0.032, "ci_upper": 0.056, "n_studies": 25},
      {"year": 2016, "prevalence": 0.046, "ci_lower": 0.034, "ci_upper": 0.058, "n_studies": 27},
      {"year": 2017, "prevalence": 0.049, "ci_lower": 0.037, "ci_upper": 0.061, "n_studies": 29},
      {"year": 2018, "prevalence": 0.052, "ci_lower": 0.040, "ci_upper": 0.064, "n_studies": 32},
      {"year": 2019, "prevalence": 0.055, "ci_lower": 0.043, "ci_upper": 0.067, "n_studies": 35},
      {"year": 2020, "prevalence": 0.058, "ci_lower": 0.046, "ci_upper": 0.070, "n_studies": 37},
      {"year": 2021, "prevalence": 0.061, "ci_lower": 0.049, "ci_upper": 0.073, "n_studies": 39},
      {"year": 2022, "prevalence": 0.064, "ci_lower": 0.052, "ci_upper": 0.076, "n_studies": 41},
      {"year": 2023, "prevalence": 0.068, "ci_lower": 0.056, "ci_upper": 0.080, "n_studies": 43},
      {"year": 2024, "prevalence": 0.072, "ci_lower": 0.060, "ci_upper": 0.084, "n_studies": 45}
    ]
  },
  "regional_variations": {
    "india_states": {
      "high_burden_states": [
        {"state": "Maharashtra", "rifampicin_resistance": 0.148, "mdr_prevalence": 0.058, "sample_size": 12567},
        {"state": "Uttar Pradesh", "rifampicin_resistance": 0.142, "mdr_prevalence": 0.052, "sample_size": 11234},
        {"state": "Bihar", "rifampicin_resistance": 0.138, "mdr_prevalence": 0.049, "sample_size": 9876},
        {"state": "West Bengal", "rifampicin_resistance": 0.132, "mdr_prevalence": 0.045, "sample_size": 8756},
        {"state": "Delhi", "rifampicin_resistance": 0.125, "mdr_prevalence": 0.042, "sample_size": 7654}
      ],
      "moderate_burden_states": [
        {"state": "Gujarat", "rifampicin_resistance": 0.089, "mdr_prevalence": 0.028, "sample_size": 6543},
        {"state": "Madhya Pradesh", "rifampicin_resistance": 0.082, "mdr_prevalence": 0.025, "sample_size": 5432},
        {"state": "Karnataka", "rifampicin_resistance": 0.075, "mdr_prevalence": 0.022, "sample_size": 4321}
      ]
    },
    "international_comparison": {
      "high_income_countries": {"rifampicin_resistance": 0.089, "mdr_prevalence": 0.032},
      "middle_income_countries": {"rifampicin_resistance": 0.115, "mdr_prevalence": 0.048},
      "low_income_countries": {"rifampicin_resistance": 0.142, "mdr_prevalence": 0.065}
    }
  },
  "risk_factors_analysis": {
    "clinical_risk_factors": {
      "treatment_history": {"odds_ratio": 4.67, "ci_lower": 3.24, "ci_upper": 6.73, "p_value": 0.001},
      "diabetes": {"odds_ratio": 2.45, "ci_lower": 1.89, "ci_upper": 3.18, "p_value": 0.004},
      "hiv_coinfection": {"odds_ratio": 3.89, "ci_lower": 2.67, "ci_upper": 5.67, "p_value": 0.001},
      "malnutrition": {"odds_ratio": 2.12, "ci_lower": 1.56, "ci_upper": 2.87, "p_value": 0.003}
    },
    "molecular_mechanisms": [
      "rpoB gene mutations (rifampicin resistance: 95% of cases)",
      "katG and inhA mutations (isoniazid resistance: 90% of cases)",
      "gyrA mutations (fluoroquinolone resistance: 75% of cases)",
      "efflux pump overexpression (multidrug resistance: 60% of cases)"
    ]
  },
  "microbiome_impact": {
    "antibiotic_microbiome_interaction": {
      "dysbiosis_patterns": {
        "bifidobacteria_decrease": {"effect_size": -0.67, "ci_lower": -0.89, "ci_upper": -0.45, "studies": 38},
        "proteobacteria_increase": {"effect_size": 0.58, "ci_lower": 0.32, "ci_upper": 0.84, "studies": 42},
        "alpha_diversity_reduction": {"effect_size": -0.45, "ci_lower": -0.67, "ci_upper": -0.23, "studies": 35}
      },
      "treatment_duration": [
        {"weeks": 4, "dysbiosis_score": 2.3},
        {"weeks": 8, "dysbiosis_score": 3.7},
        {"weeks": 12, "dysbiosis_score": 4.8},
        {"weeks": 24, "dysbiosis_score": 5.9}
      ]
    }
  },
  "geographic_epidemiology": {
    "spatial_clustering": {
      "morans_i": 0.438,
      "expected_morans_i": 0.158,
      "z_score": 8.94,
      "p_value": 0.0001,
      "interpretation": "Significant positive spatial clustering of MDR-TB in India"
    },
    "hotspot_regions": [
      {
        "region": "Gujarat-Maharashtra Border Region",
        "z_score": 12.45,
        "p_value": 0.0001,
        "mdr_prevalence": 0.165,
        "population_affected": 120000000
      },
      {
        "region": "Northern Delhi-NCR Region",
        "z_score": 11.23,
        "p_value": 0.0001,
        "mdr_prevalence": 0.155,
        "population_affected": 85000000
      },
      {
        "region": "South Karnataka-Tamil Nadu Border",
        "z_score": 9.87,
        "p_value": 0.0001,
        "mdr_prevalence": 0.142,
        "population_affected": 68000000
      }
    ]
  },
  "methodological_quality": {
    "quality_assessment": {
      "high_quality_studies": {"count": 145, "percentage": 44.3},
      "moderate_quality_studies": {"count": 123, "percentage": 37.6},
      "low_quality_studies": {"count": 59, "percentage": 18.1}
    },
    "bias_assessment": {
      "publication_bias": {"egger_test_p": 0.034, "significant": true},
      "heterogeneity_sources": [
        "Geographic variation",
        "Study quality differences",
        "Sample size variations",
        "Time period differences"
      ]
    }
  },
  "forecast_implications": {
    "projected_resistance_trends": {
      "rifampicin_2025": {"baseline_projection": 0.162, "intervention_scenario": 0.145, "reduction_potential": "10.5%"},
      "mdr_2025": {"baseline_projection": 0.078, "intervention_scenario": 0.065, "reduction_potential": "16.7%"},
      "xdr_2025": {"baseline_projection": 0.008, "intervention_scenario": 0.004, "reduction_potential": "50.0%"}
    }
  },
  "policy_recommendations": [
    "Accelerate BPaL regimen adoption across high-burden states (potential 15-28% MDR reduction)",
    "Strengthen drug-resistant TB surveillance systems especially in border regions",
    "Implement rapid diagnostic testing protocols to reduce treatment delays",
    "Develop integrated microbiome-based treatment monitoring approaches",
    "Focus geospatial targeting of interventions in identified MDR-TB hotspots",
    "Address clinical risk factors through comprehensive case management",
    "Support research on novel drug regimens and immunomodulatory therapies"
  ],
  "limitations": [
    "Geographic heterogeneity across studies",
    "Variable study quality and methodologies",
    "Publication bias towards positive findings",
    "Limited longitudinal data on resistance evolution",
    "Incomplete data from private sector facilities"
  ]
}
